


Western Markets Hold Back Global Growth For Neurology Drugs

LONDON, GREATER LONDON, UK, November 28, 2018 / EINPresswire.com/ -- As a new report, Pharmaceutical Drugs Global Market **Opportunities And Strategies To 2021**, from The Business Research Company, shows, North America and Western Europe, the world's two largest markets for neurology drugs to treat diseases of the brain, spinal cord and nerves, are holding back global growth to around 5% annually, despite vigorous growth in other regions. Asia Pacific's market, which is nearly as large as that of Western Europe, will grow at almost 9% year on year to 2021, and so will the smaller market of the Middle East. Africa and South America will also see above average



growth. Increased incidence of age-related disease in the developed world and greater affordability of treatments with growing GDP per capita in the emerging markets help account for growth in the markets for these drugs.

Neurology drugs are used to treat conditions such as epilepsy, Alzheimer's disease and other dementias, cerebrovascular diseases including stroke, migraine and other headache disorders, multiple sclerosis, Parkinson's disease, neuroinfections, traumatic disorders of the nervous system due to head trauma, and neurological disorders as a result of malnutrition. Anaesthetics is the largest subsegment in the neurology (central nervous system) drugs market and its growth rate is accelerating. The high market size for this segment can be attributed to the rising prevalence of preventive surgery for cardiovascular diseases and chronic respiratory diseases. Analgesics is the fastest-growing segment, but is maintaining a stable growth rate rather than an accelerating one; anti-epileptics growth rate is also stable but at a much slower pace than analgesics, while both anti-Parkinson drugs and other central nervous system drugs are showing a slight decline in their growth rates.

The top selling neurological medications in 2016 include Copaxone, Lyrica, and Tecfidera. The market for neurology drugs is more concentrated than that for most drugs, as the leading ten competitors account for two-thirds of the total instead of, as in the case of cardiovascular drugs, around one-third. America's Biogen is the market leader, closely followed by the Swiss Hoffman-La Roche, both with close to 12% of global sales; Johnson and Johnson is in third place with about an about 9% share.

Pharmaceutical Drugs Global Market Opportunities And Strategies To 2021 is one of a series of new industry reports from The Business Research Company that identify opportunities and explain strategies in over 300 markets, covering over 2400 market segments and 56 geographies. It provides a pharmaceutical industry overview, pharmaceutical industry analysis, past drug industry statistics and forecasts. Like the other reports in the series it also provides market growth rates, market trends, market drivers, market restraints, market revenues, market shares and company profiles of the leading competitors. These industry reports draw on 150,000 datasets. Extensive secondary research is augmented with exclusive insights and quotations from industry leaders obtained through interviews. Market analysis and forecasts are provided by a highly experienced and expert team of analysts and modelers. Key actionable strategies are explained and opportunities identified by country and segment.

Where To Learn More

Read the Pharmaceutical Drugs Global Market Opportunities And Strategies To 2021 from The Business Research Company for more information on the following:

Markets Covered: Pharmaceutical drugs, healthcare market, musculoskeletal disorders drugs, cardiovascular drugs, oncology drugs, anti-infective drugs, metabolic disorders drugs, central nervous system drugs, genito-urinary drugs, respiratory diseases drugs, gastrointestinal drugs, hematology drugs, dermatology drugs, ophthalmology drugs

Pharmaceutical Drugs Market Companies Covered: Novartis AG, Sanofi S.A., F. Hoffmann-La Roche Ltd., Pfizer Inc., Gilead Sciences, Inc., Johnson & Johnson, GlaxoSmithKline Plc., Bayer AG, Teva Pharmaceuticals, Merck & Co.

Regions: North America, Asia Pacific, Western Europe, South America, Eastern Europe, Middle East, Africa.

Countries: USA, China, UK, Japan, France, Germany, Australia, India, Spain, Russia, Italy, Brazil Time Series: Five years historic (2013-17) and forecast (2017-21).

Data Segmentations: Pharmaceutical drugs market size, historic and forecast size and growth rates for the world, 7 regions and 12 countries, pharmaceutical drugs market split by segments (musculoskeletal disorders drugs, cardiovascular drugs, oncology drugs, anti-infective drugs, metabolic disorders drugs, central nervous system drugs, genito-urinary drugs, respiratory diseases drugs, gastrointestinal drugs, hematology drugs, dermatology drugs, ophthalmology drugs) historic and forecast size, segment shares, and growth rates for the world, 7 regions and 12 countries, global competitor sales and market shares.

Healthcare market segment shares for the world, 7 regions and 12 countries.

Other Data: Per capita average pharmaceutical drugs expenditure and pharmaceutical drugs market size as a percentage of GDP, global and by country; number of general practitioners, average pharmaceutical drugs revenue per general practitioner, number of pharmacies per 100,000 population, number of pharmacists, average pharmaceutical drugs revenue per pharmacist, number of employees in pharmaceutical industry, average revenue per pharmaceutical employee, number of pharmaceutical enterprises, average pharmaceutical drugs revenue per pharmaceutical enterprise, generic & branded sales proportion by country

(value), and new drug approvals- 2017, by country

Other Information: Drivers and restraints of the global pharmaceutical drugs market, PESTEL analysis, pharmaceutical drugs market customer information, company profiles including products, strategy and financial performance for 5 pharmaceutical drugs companies, pharmaceutical drugs market trends and strategies, pharmaceutical drugs market key mergers and acquisitions

Strategies For Participants In The Pharmaceutical Industry: The report identifies over 20 actionable strategies based on trends or key companies' approaches, including Pfizer's growth strategy, which aims at moving towards the biopharmaceutical industry by the end of the decade, and Eli Lilly's growth strategy, which is to strengthen its market position in the global biosimilars market.

Opportunities For Pharmaceutical Companies: The report identifies the global, regional and country subsegments where the pharma and healthcare market will put on most \$ sales up to 2022.

Sourcing and Referencing: Data and analysis throughout the report are sourced using end notes. Sources include primary as well as extensive secondary research.

Number of Figures in the report: 151

Number of Tables in the report: 151

Interested to know more? Here is a list of reports similar to "Pharmaceutical Drugs Global Market Opportunities And Strategies To 2021": <u>Anti-Infective Drugs Global Market Report 2018</u> Cardiovascular Drugs Global Market Report 2018(<u>https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-globalmarket-report-2018</u>) Central Nervous System Drugs Global Market Report(<u>https://www.thebusinessresearchcompany.com/report/central-nervous-system-drugs-globalglobal-market-report-2018</u>

Oliver Guirdham The Business Research Company +44 20 7193 0708 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.